首页> 美国卫生研究院文献>Clinical and Experimental Immunology >The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation
【2h】

The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation

机译:人类心脏移植术后急性排斥反应中的直接和间接同种异体呈递途径

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alloreactive T cells may be activated via a direct or an indirect antigen presentation pathway. We questioned whether the frequency of interferon (IFN)-γ producing cells determined by enzyme-linked immunospot (ELISPOT) assay is an effective tool to monitor the direct and/or indirect presentation pathway. Secondly, we wondered whether early and late acute rejection (AR) are associated with both pathways. Before (n = 15), during (n = 18) and after (n = 16) a period of AR, peripheral blood mononuclear cell (PBMC) samples were tested from 13 heart transplant recipients. The direct presentation pathway was always present. The number of IFN-γ producing cells reactive to this pathway increased significantly (P = 0·04) during AR and the number decreased (P = 0·005) after AR therapy. In contrast, the indirect allogeneic presentation pathway was present in only eight of 18 AR samples. When the indirect presentation pathway was detectable, it increased significantly during AR. Five of eight of these AR occurred more than 6 months after transplantation. The ELISPOT assay, enumerating alloreactive IFN-γ producing cells, is a valuable tool to determine the reactivity via both the direct and the indirect presentation pathway. The direct presentation pathway always plays a role in AR, while the indirect pathway contributes especially to late AR.
机译:可以通过直接或间接抗原呈递途径激活同种反应性T细胞。我们质疑通过酶联免疫斑点法(ELISPOT)测定的干扰素(IFN)-γ产生细胞的频率是否是监测直接和/或间接呈递途径的有效工具。其次,我们想知道早期和晚期急性排斥反应(AR)是否与这两种途径有关。在AR期之前(n = 15),期间(n = 18)和之后(n = 16),从13位心脏移植受者中检测了外周血单核细胞(PBMC)样品。直接展示途径一直存在。在AR期间,与该途径反应的产生IFN-γ的细胞数目显着增加(P = 0·04),而在AR治疗后数目减少(P = 0·005)。相反,间接的同种异体呈递途径仅存在于18个AR样品中的8个中。当检测到间接呈递途径时,它在AR期间显着增加。这些AR中有八分之五发生在移植后6个月以上。列举同种异体反应性IFN-γ产生细胞的ELISPOT分析是一种通过直接和间接呈递途径确定反应性的有价值的工具。直接呈递途径始终在AR中发挥作用,而间接呈递尤其有助于晚期AR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号